Search is Powered by Google
Follow us on:
Follow our health news on Twitter
Follow Our News on Facebook
Personalization
login | register
Muscular Dystrophy / ALS News

New Drug For Muscular Dystrophy Promises Benefit Without Risk Of Infection

Main Category: Muscular Dystrophy / ALS
Also Included In: Immune System / Vaccines
Article Date: 12 Jun 2009 - 2:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:5 stars

4.6 (5 votes)

Health Professional:4 stars

4 (1 votes)

Article Opinions: 0 posts

A new drug being studied for the treatment of muscle degenerating diseases has shown promising results. According to a study published in the British Journal of Pharmacology, Debio 025 is as effective as current drugs but, crucially, does not cause unwanted immunosuppressive effects.

Bethlem Myopathy and Ullrich Congenital Muscular Dystrophy (UCMD) are muscle wasting diseases caused by deficiencies in collagen VI, a component of connective tissue. Patients are usually diagnosed at birth and suffer from muscle weakness that worsens over time. UCMD patients often also suffer respiratory failure, which is complicated by lung infections. Although the drug cyclosporin A (CsA) offers some benefit for these patients, its long term use may be undesirable because it interacts with calcineurin, an important immunoregulatory protein.

"Long-term treatment with CsA is risky because it suppresses the immune system, making patients more susceptible to life-threatening lung infections," says Paolo Bernardi, who led the team at the University of Padova in Italy. "Our findings suggest Debio 025 may provide a safer alternative".

In the study, mice suffering from a muscle-wasting disease similar to human muscular dystrophy were protected when treated with Debio 025. The researchers studied muscle cells from mice given the drug for five days and found decreases in numbers of abnormal muscle fibres similar to those reported in studies of treatment with CsA. They were also able to show that Debio 025, although related to CsA, was not targeting calcineurin.

"This drug has no effects on the immune system and therefore could be used for prolonged periods of time without increasing risk of infection. We should be able to treat children affected by these forms of muscular dystrophy and possibly slow down or even stop the progression of the disease," says Bernardi.

Source:
Jennifer Beal
Wiley-Blackwell




Personalized Homepage Weekly Newsletters Daily News Alerts
Hemophilia Opioid Induced Constipation Pneumococcal Disease ADHD Anxiety Asthma Atrial Fibrillation Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Please fill in our survey

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
What Is Ataxia? What Causes Ataxia?
31 Aug 2009
Ataxia is a lack of muscle coordination which may affect speech, eye movements, the ability to swallow, walking, picking up objects and other voluntary movements. A person with persistent ataxia may have damage in the part...


Menopause - The Ups and Downs of Change
Menopause - The Ups and Downs of Change

Menopause brings with it physical and emotional changes. But there are advantages to this time of life.

more videos are available in our health videos section.